This content is in French.
NB-UVB: light that heals?
19 septembre 2025
By Ana Espino | Published on september 19, 2025 | 3 min read
#Vitiligo #Immunity #Phototherapy #NB-UVB
Vitiligo — a chronic autoimmune disease — is characterized by progressive depigmentation of the skin, caused by the destruction of melanocytes. Although not life-threatening, this condition has a profound psychological and social impact, especially in younger patients. Despite the wide range of existing treatments — topical corticosteroids, calcineurin inhibitors, phototherapy — no protocol guarantees stable and complete repigmentation, particularly in extensive or resistant forms.
In this context, new combination strategies are being explored to optimize clinical outcomes. Tofacitinib, a JAK inhibitor, has recently emerged as a promising targeted therapy, acting on the inflammatory pathway involved in melanocyte destruction. When combined with NB-UVB phototherapy, it may promote faster and more complete repigmentation. The objective of this study was to evaluate the efficacy and safety of the NB-UVB + tofacitinib combination, compared with phototherapy alone, in patients with vitiligo.
#Vitiligo #Immunity #Phototherapy #NB-UVB
Vitiligo — a chronic autoimmune disease — is characterized by progressive depigmentation of the skin, caused by the destruction of melanocytes. Although not life-threatening, this condition has a profound psychological and social impact, especially in younger patients. Despite the wide range of existing treatments — topical corticosteroids, calcineurin inhibitors, phototherapy — no protocol guarantees stable and complete repigmentation, particularly in extensive or resistant forms.
In this context, new combination strategies are being explored to optimize clinical outcomes. Tofacitinib, a JAK inhibitor, has recently emerged as a promising targeted therapy, acting on the inflammatory pathway involved in melanocyte destruction. When combined with NB-UVB phototherapy, it may promote faster and more complete repigmentation. The objective of this study was to evaluate the efficacy and safety of the NB-UVB + tofacitinib combination, compared with phototherapy alone, in patients with vitiligo.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Guo, X., et al. (2025). The efficacy of narrowband ultraviolet B phototherapy combination with tofacitinib in the treatment of vitiligo: a randomized controlled trial. Journal of Dermatological Treatment, 36(1), 2479567
View the source
